No black box warning on record for Journavx

As of the latest FDA labeling reviewed, Journavx (SUZETRIGINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Journavx medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Moderate and Severe Hepatic Impairment : Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Use in patients with moderate hepatic impairment may increase the risk of adverse reactions. The recommended dosage is lower in patients with moderate hepatic impairment (Child-Pugh Class B) than those with normal hepatic function. ( 5.4 ) 5.1 Increased Ris

No black box warning on record for Journavx

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Moderate and Severe Hepatic Impairment : Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Use in patients with moderate hepatic impairment may increase the risk of adverse reactions. The recommended dosage is lower in patients with moderate hepatic impairment (Child-Pugh Class B) than those with normal hepatic function. ( 5.4 ) 5.1 Increased Ris

Journavx Black Box Warning

No black box warning on record for Journavx

Other warnings & precautions

Journavx Black Box Warning

No black box warning on record for Journavx

Other warnings & precautions